Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Results of Operations and Financial Condition

Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02

Results of Operation and Financial Condition

On April 27, 2017, Versartis, Inc. (the Company) issued a press
release announcing its financial results for the three-month
period ended March 31, 2017. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.

The information in this Item 2.02 and in the press release
attached as Exhibit 99.1 to this Current Report on Form 8-K shall
not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section or Sections 11 and 12(a)(2) of
the Securities Act of 1933, as amended. The information contained
in this Item 2.02 and in the press release attached as Exhibit
99.1 to this Current Report on Form 8-K shall not be incorporated
by reference into any filing with the U.S. Securities and
Exchange Commission made by the Company, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on
Form 8-K.

Exhibit

No.

Description

99.1

Press Release, issued by Versartis, Inc. on April 27,
2017.


About Versartis, Inc. (NASDAQ:VSAR)

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.

Versartis, Inc. (NASDAQ:VSAR) Recent Trading Information

Versartis, Inc. (NASDAQ:VSAR) closed its last trading session down -0.10 at 19.80 with 187,380 shares trading hands.

An ad to help with our costs